OGN · Organon & Co.
$13.52
-0.15% last session
End-of-day data · updated 2026-07-28
Market cap
$4B
Enterprise value
$11B
Trailing P/E
14.6
Forward P/E
3.7
Dividend yield
1.0%
Beta
1.54
Avg volume
4M
Employees
10K
2D change
—
5D change
-0.15%
10D change
0.15%
30D change
0.30%
60D change
1.50%
MTD change
0.07%
YTD change
89.59%
Analyst Outlook
Analyst estimates change daily — follow the shifts on the Estimate Trends page.
Technical Analysis
Analyst sentiment over time — OGN
Rec Mean (blue, left — higher = more bullish) vs. price targets (right).
Investment Bank Ratings as of 2026-04-29
Latest call per bank · past 12 months
Barclays
Underweight$8.00
-40.8% vs priceJP Morgan
Underweight$12.00
-11.2% vs priceMorgan Stanley
Equal-Weight$9.00
-33.4% vs priceRecent rating actions
| Date | Firm | Action | Rating | Price target |
|---|---|---|---|---|
| 2026-04-29 | BNP Paribas | Downgrade | Outperform → Neutral | $12.00 → $14.00 |
| 2026-04-28 | Piper Sandler | Upgrade | Underweight → Neutral | $5.00 → $14.00 |
| 2026-02-24 | Barclays | Maintains | Underweight | $7.50 → $8.00 |
| 2025-12-09 | Barclays | Initiates | Underweight | $0.00 → $7.50 |
| 2025-11-11 | JP Morgan | Maintains | Underweight | $14.00 → $12.00 |
| 2025-11-11 | Morgan Stanley | Maintains | Equal-Weight | $10.00 → $9.00 |
Ratings and price targets are the published opinions of the issuing banks, compiled from Yahoo Finance rating actions — not investment advice.
Signal Summary as of 2026-07-28
- RSI (14): RSI is 60 — neutral momentum, neither overbought nor oversold.
- Price vs 50-day MA: Trading 0.5% above the 50-day MA ($13.45).
- Price vs 200-day MA: Trading 43.1% above the 200-day MA ($9.45).
- MA cross: The 50-day MA sits above the 200-day MA (golden-cross regime) — the longer-term trend points up.
- MACD (12,26,9): MACD histogram is negative (-0.02) — short-term momentum is fading.
- 52-week range: Price is within 5% of the 52-week high ($13.56).
OGN Price Chart
Loading chart for OGN…
Fundamentals
About Organon & Co.
Organon & Co. develops and delivers women health solutions through prescription therapies and medical devices in the United States, Europe, Canada, Japan, rest of the Asia Pacific, China, Latin America, the Middle East, Russia, Africa, and internationally. The company's women's health portfolio comprises contraception and fertility brands, such as Nexplanon, a long-acting reversible contraceptive; NuvaRing, a monthly vaginal contraceptive ring; Cerazette, Marvelon, and Mercilon to prevent pregnancy; Follistim AQ, which is used to promote development of ovarian follicles; Elonva, a follicle stimulant; Ganirelix acetate injection, an injectable antagonist; Jada for abnormal postpartum uterine bleeding and hemorrhage; and Xaciato for bacterial vaginosis. Its biosimilars portfolio consists of immunology products, such as Brenzys, Renflexis, and Hadlima; oncology products, including Ontruzant and Aybintio; Bildyos and Bilprevda, a recombinant anti-RANKL human monoclonal antibodies; and Poherdy, a neu receptor antagonist. The company also offers cholesterol-modifying medicines under the Zetia, Ezetrol, Vytorin, Inegy, Atozet, Rosuzet, and Zocor brands; Cozaar and Hyzaar for hypertension; respiratory products to control and prevent asthma symptoms under the Singulair, Dulera, Zenhale, and Asmanex brands, as well as seasonal allergic rhinitis under the Nasonex, Clarinex, and Aerius brands. In addition, it provides dermatology products under the Vtama, Diprosone, and Elocon brand; bone health products under the Fosamax brand; and non-opioid pain management products under the Arcoxia, Diprospan, and Celestone brands, as well as Proscar for symptomatic benign prostatic hyperplasia; and Propecia for male pattern hair loss. The company serves drug wholesalers and retailers, hospitals, clinics, government agencies, health maintenance organizations, pharmacy benefit managers, and other institutions. Organon & Co. was founded in 1923 and is headquartered in Jersey City, New Jersey.
More in Drug Manufacturers - General
Data is sourced from end-of-day snapshots and refreshed daily before the US market open — nothing on this page is real-time. Figures can contain vendor errors. This page is for information only and is not investment advice.